Viral RNA and DNA trigger common antiviral responses in mesangial cells.
about
Polyene macrolide antifungal drugs trigger interleukin-1β secretion by activating the NLRP3 inflammasomeAnti-GBM glomerulonephritis involves IL-1 but is independent of NLRP3/ASC inflammasome-mediated activation of caspase-1.Distinct contributions of TNF receptor 1 and 2 to TNF-induced glomerular inflammation in mice.Nephrotic-range proteinuria on interferon-β treatment: immune-induced glomerulonephritis or other pathway?Mdm2 promotes systemic lupus erythematosus and lupus nephritisTubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific AntibodiesStructural modification of DNA--a therapeutic option in SLE?A novel pathogenetic concept-antiviral immunity in lupus nephritis.Danger control programs cause tissue injury and remodeling.Inflammatory chemokine expression via Toll-like receptor 3 signaling in normal human mesangial cells.Macrophage-mediated glucolipotoxicity via myeloid-related protein 8/toll-like receptor 4 signaling in diabetic nephropathy.Immunopathology of lupus nephritis.Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis.Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing.Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway.Association between -1486 T>C and +1174 G>A single nucleotide polymorphisms in TLR9 gene and severity of lupus nephritis.Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 mRNA translation.A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort.The pathogenesis of lupus nephritis.Toll-like receptors in lupus nephritis.Polyinosinic-polycytidylic acid induces the expression of interferon-stimulated gene 20 in mesangial cells.
P2860
Q33916170-C164FAC4-97FA-4BC7-B65B-7141BF5E6950Q34064677-41D9B2CA-426C-4685-AA32-29803BDA926EQ34837575-0B7AA283-B2E4-4EB2-85EA-7F8C62F5B8FEQ35227661-7D0A9BE4-6C7F-4CA7-89EE-AABF030CAA27Q35758450-DD6E5D35-9C67-433B-8B9D-627847164294Q37052024-FB269272-2295-479F-955D-2B6137180585Q37947116-14C79398-27DE-4402-AD7F-A7C1C753D3F8Q37976347-6E1DE627-D0FB-44BE-A7B0-5AE6137826F8Q38113929-F3DB391C-D8E3-439D-BE32-0BEB9E79D650Q38128300-6DB900F2-D948-4FFE-B091-11C1E5667F10Q38172884-6CB8414A-00A5-46F4-9A86-2B09D40F94D2Q38176819-F1B1AC2C-9F69-4E31-BE59-CCF00DD9623DQ38206875-BB457C16-8CEF-490F-B738-97EBA36EF3CCQ39603954-F813A9C1-4B05-479C-A92F-B6EBC6BA760BQ41937471-E40F96A3-9CCE-4FA7-B2CC-A353C8339F45Q42111635-9A6CFC16-DF22-45DF-B81B-821858569701Q50163262-8CAB9153-06FC-437A-9E16-31B2F24EC736Q51812367-88D11436-4EF7-4E83-8D34-80D6A967E462Q51868414-96862982-E57F-4928-A078-244C94A05EF0Q52323268-C2EAA0F7-B310-4519-A3B2-99081DBCED04Q54568507-3E3420C1-FB0B-4F70-B717-A2F80E7A1D40
P2860
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
@en
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
@nl
type
label
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
@en
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
@nl
prefLabel
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
@en
Viral RNA and DNA trigger common antiviral responses in mesangial cells.
@nl
P2093
P2860
P356
P1476
Viral RNA and DNA trigger common antiviral responses in mesangial cells
@en
P2093
Anela Taubitz
Anton G Moll
Julia Lichtnekert
Volker Vielhauer
P2860
P304
P356
10.1681/ASN.2008101067
P577
2009-08-27T00:00:00Z